Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Buprenorphine Header

    Virtual Booth

    Contact Supplier

    Buprenorphine

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SCI PHARMTECH Buprenorphine

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Buprenorphine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 15,127Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Study: Monthly Subloclade® for Opioid Use Disorder in Pregnancy
    Study: Monthly Subloclade® for Opioid Use Disorder in Pregnancy

    01 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-study-highlights-monthly-sublocade-as-a-potential-treatment-option-for-opioid-use-disorder-during-and-after-pregnancy-302444173.html

    PR NEWSWIRE
    01 May 2025
    Share Share
    Amid market headwinds, Indivior's Sublocade gains FDA nod
    Amid market headwinds, Indivior's Sublocade gains FDA nod

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-release-injection-302382920.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    Indivior Announces FDA Approval of Label Changes for Sublocade
    Indivior Announces FDA Approval of Label Changes for Sublocade

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-release-injection-302382920.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    Indivior Issue Statement On Delayed Approval Of Subloclade Label
    Indivior Issue Statement On Delayed Approval Of Subloclade Label

    12 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-statement-re-delayed-fda-approval-of-sublocade-label-changes-302374307.html

    PR NEWSWIRE
    12 Feb 2025
    Share Share
    ZIM Lab & Neuraxpharm Authorized Buprenorphine Marketing
    ZIM Lab & Neuraxpharm Authorized Buprenorphine Marketing

    10 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/zim-laboratories-and-neuraxpharm-granted-marketing-authorization-for-buprenorphine-sublingual-film-in-europe-16651

    INDPHARMAPOST
    10 Jan 2025
    Share Share
    AstraZeneca cans ph. 2 OUD drug over antifungal interaction
    AstraZeneca cans ph. 2 OUD drug over antifungal interaction

    23 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/astrazeneca-cans-phase-2-opioid-use-disorder-drug-over-interaction-antifungal

    FIERCE BIOTECH
    23 Nov 2024
    Share Share